Perioperative changes in cell-free DNA for patients undergoing surgery for colon cancer.
Cell-free DNA
Colon Cancer
Complications
Perioperative
Surgery
Surgical stress
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
06 Apr 2022
06 Apr 2022
Historique:
received:
13
12
2021
accepted:
17
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Various conditions with cellular decay are associated with elevated cell-free DNA (cfDNA). This study aimed to investigate if perioperatively measured cfDNA levels were associated with the surgical approach, complications, or recurrence. Plasma was obtained from patients who underwent surgery for colon cancer at admission and at the time of discharge. Quantitative measurement of cfDNA was performed by amplifying two amplicons of 102 base pairs (bp) and 132 bp of Beta-2-Microglobulin (B2M) and Peptidyl-Prolyl cis-trans Isomerase A (PPIA), respectively. cfDNA was measured in 48 patients who underwent surgery for colonic cancer. Sixteen patients had recurrence during the follow-up period, fifteen developed a postoperative complication, and seventeen patients developed neither, acting as the control group. Postoperative cfDNA levels were significantly elevated from baseline samples, across all groups, with a median preoperatively B2M level of 48.3 alleles per mL and postoperatively of 220 alleles per mL and a median preoperatively level PPIA of 26.9 alleles per mL and postoperatively of 111.6 alleles per mL (p < 0.001 for B2M and p < 0.001 for PPIA). Postoperative levels of PPIA, but not B2M, were significantly higher in patients experiencing complications than in the control group (p = 0.036). However, a tendency towards an association between the surgical approach and the changes in cfDNA levels was found for PPIA (p = 0.058), and B2M (p = 0.087). Plasma cfDNA was increased after surgery in all patients with colon cancer. Postoperative PPIA levels were significantly higher in patients experiencing surgical complications but not in B2M levels.
Sections du résumé
BACKGROUND
BACKGROUND
Various conditions with cellular decay are associated with elevated cell-free DNA (cfDNA). This study aimed to investigate if perioperatively measured cfDNA levels were associated with the surgical approach, complications, or recurrence.
METHODS
METHODS
Plasma was obtained from patients who underwent surgery for colon cancer at admission and at the time of discharge. Quantitative measurement of cfDNA was performed by amplifying two amplicons of 102 base pairs (bp) and 132 bp of Beta-2-Microglobulin (B2M) and Peptidyl-Prolyl cis-trans Isomerase A (PPIA), respectively.
RESULTS
RESULTS
cfDNA was measured in 48 patients who underwent surgery for colonic cancer. Sixteen patients had recurrence during the follow-up period, fifteen developed a postoperative complication, and seventeen patients developed neither, acting as the control group. Postoperative cfDNA levels were significantly elevated from baseline samples, across all groups, with a median preoperatively B2M level of 48.3 alleles per mL and postoperatively of 220 alleles per mL and a median preoperatively level PPIA of 26.9 alleles per mL and postoperatively of 111.6 alleles per mL (p < 0.001 for B2M and p < 0.001 for PPIA). Postoperative levels of PPIA, but not B2M, were significantly higher in patients experiencing complications than in the control group (p = 0.036). However, a tendency towards an association between the surgical approach and the changes in cfDNA levels was found for PPIA (p = 0.058), and B2M (p = 0.087).
CONCLUSIONS
CONCLUSIONS
Plasma cfDNA was increased after surgery in all patients with colon cancer. Postoperative PPIA levels were significantly higher in patients experiencing surgical complications but not in B2M levels.
Identifiants
pubmed: 35387596
doi: 10.1186/s12876-022-02217-w
pii: 10.1186/s12876-022-02217-w
pmc: PMC8988386
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
168Informations de copyright
© 2022. The Author(s).
Références
Int J Cancer. 2014 Dec 15;135(12):2984-91
pubmed: 24798213
Ann Oncol. 2019 Jul 1;30(7):1088-1095
pubmed: 31046124
BMC Cancer. 2012 Sep 25;12:428
pubmed: 23009708
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9236-41
pubmed: 10430926
Crit Care. 2017 Jan 24;21(1):14
pubmed: 28118843
Acta Anaesthesiol Scand. 2017 Oct;61(9):1084-1094
pubmed: 28766696
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Clin Cancer Res. 2012 Feb 15;18(4):1177-85
pubmed: 22228631
Surg Endosc. 1999 Mar;13(3):233-5
pubmed: 10064753
J Surg Oncol. 2015 Oct;112(5):538-43
pubmed: 26271357
Dis Colon Rectum. 2018 Sep;61(9):1016-1025
pubmed: 30086050
Intensive Care Med. 2016 Apr;42(4):551-561
pubmed: 26912315
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
Ann Surg Oncol. 2003 Oct;10(8):972-92
pubmed: 14527919
Oncotarget. 2016 Dec 20;7(51):85430-85436
pubmed: 27863426
Int J Cancer. 2021 Apr 1;148(7):1665-1675
pubmed: 33320961
Mol Oncol. 2020 Aug;14(8):1670-1679
pubmed: 32471011
Medicine (Baltimore). 2015 Oct;94(42):e1786
pubmed: 26496309
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Hum Genet. 2016 Aug;24(8):1167-74
pubmed: 26757983
Biol Res Nurs. 2016 Oct;18(5):477-88
pubmed: 27067611
Transl Oncol. 2018 Oct;11(5):1220-1224
pubmed: 30086420
Clin Transl Immunology. 2016 Apr 29;5(4):e77
pubmed: 27195120